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A 31-year-old man with sigmoid colon cancer with concomitant simultaneous multiple liver metastases had
received FOLFIRI (leucovorin, fluorouracil and irinotecan) and FOLFOX6 (leucovorin, fluorouracil and oxaliplatin) after
an ordinary sigmoidectomy. However, his serum carcinoembryonic antigen (CEA) level increased rapidly during the
fifteen months after the operation while he was on FOLFOX6. Abdominal computed tomography revealed
expanding multiple liver tumors. As the third line chemotherapy, a combination therapy of cetuximab with
irinotecan was given, which markedly reduced his levels of serum CEA, and the size and number of liver tumors. He
underwent lateral segmentectomy of the liver and microwave coagulation of the liver metastases in the remnant
liver. Thereafter, a good quality of life with tumor dormancy was obtained for 6 months. However, his serum CEA
started to rise again in the absence of liver tumors. Therefore, FOLFOX6 with bevacizumab was chosen as the
fourth line chemotherapy, and the serum CEA was reduced with tumor dormancy. A good quality of life was
obtained again at 3 years after the first surgery. This report indicates the effectiveness of sandwiched liver surgery
with the molecular targeting drugs cetuximab and bevacizumab on multiple liver metastases of colon cancer, and
suggests the possibility of a regimen consisting of bevacizumab following cetuximab.
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Sandwiched liver surgeryBackground
Recently, various molecular targeting drugs have
appeared through developing biotechnology [1]. Cetux-
imab, a new molecular drug, has a notable ability as an
anti-epidermal growth factor receptor (EGFR) mono-
clonal antibody [2]. A randomized European study sug-
gested that cetuximab was effective in patients with
irinotecan-refractory metastatic colorectal cancer [3].
A KRAS mutation is an important predictive factor for
resistance to cetuximab chemotherapy in patients with
metastatic colorectal cancer [4]. Moreover, it has been* Correspondence: yoichitoyama@jikei.ac.jp
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reproduction in any medium, provided the orreported that the combination of cetuximab and
chemotherapy improves the resectability of colorectal
cancer liver metastases (CCLM) [5]. Bevacizumab, an
anti-vascular endothelial growth factor receptor
(VEGFR) monoclonal antibody, is also an important
drug among these new agents [6]. An open-label study,
NO16966, reported the non-inferiority of XELOX
(capecitabine and oxaliplatin) to FOLFOX4 (leucovorin
(LV), fluorouracil and oxaliplatin) for the first line
treatment of metastatic colorectal cancer; however, the
additive effect of bevacizumab to the two chemothera-
pies was not ultimately observed [7-9]. However, the
addition of bevacizumab to FOLFOX4 was effective in
metastatic colorectal cancer, including in patients with
CCLM after first line chemotherapy with FOLFIRI (LV,
fluorouracil and irinotecan) [10]. Furthermore, somel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Computed tomography demonstrated expanding multiple liver metastases of the sigmoid colon cancer after FOLFIRI and
FOLFOX6 therapy.
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in advanced colorectal cancer refractory to irinotecan,
oxaliplatin or cetuximab [11-14]. We herein report a
young male patient with CCLM who was treated suc-
cessfully by a timely sandwiched liver surgery with
the molecular targeting drugs, cetuximab and bevaci-
zumab after treatment with FOLFIRI and FOLFOX
regimens.
Case presentation
A 31-year-old man complained of melena and under-
went a colonoscopy that identified a two-thirds circum-
ferential type 2 tumor, an advanced sigmoid cancer.
Abdominal computed tomography (CT) showed nu-
merous CCLM. The patient underwent a sigmoidect-
omy with standard lymph node dissection in our
department and histopathological findings revealed a
moderately differentiated adenocarcinoma.
The patient underwent conventional neoadjuvant
chemotherapy, first with FOLFIRI (5-fluorocil (FU)
400 mg/m2 bolus injection; LV 400 mg/m2/2 hours; 5FU
2,400 to 3,000 mg/m2/46 hours continuous infusion with
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Figure 2 Changes in the serum carcinoembryonic antigen
levels of the patient with colon liver metastases after
sigmoidectomy.twenty courses). He was then commenced on FOLFOX6
(Day 1: 5FU 400 mg/m2 bolus injection; LV 200 mg/m2/
2 hours; 5FU 600 mg/m2/22 hours continuous infusion
with oxaliplatin (L-OHP) 85 mg/m2/2 hours; Day 2:
same menu without L-OHP, every 2 weeks for eight
courses) because abdominal enhanced CT demonstrated
enlargement of the CCLM according to Response Evalu-
ation Criteria in Solid Tumors (RECIST) (Figure 1).
However, in spite of the intensive neoadjuvant che-
motherapies, his serum carcinoembryonic antigen (CEA)
level gradually increased during the fifteen months fol-
lowing the first operation (Figure 2). Since the cancer
cells were found to have wild type KRAS, a combination
therapy of cetuximab with irinotecan was chosen as the
third line chemotherapy, considering the possibility of
liver surgery for the CCLM. The patient received weekly
cetuximab (400 mg/m2 initial dose and 250 mg/m2 per
week thereafter) and bi-weekly irinotecan (150 mg/m2).
One course of the combination therapy was defined as
7 weeks (six administrations of cetuximab and three
administrations of irinotecan, followed by one week’s
rest). Although the patient initially suffered from facial
eczema due to the cetuximab (Figure 3), follow-upFigure 3 Face eczema appeared as a principal side effect of
cetuximab.
Figure 4 Reduction of tumor volume in the liver after the cetuximab and irinotecan treatment. (a) Computed tomography before and (b)
after the combination treatment with cetuximab and irinotecan.
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tion in the size and number of CCLM (Figure 4), and
the serum CEA decreased significantly (Figure 2).
To obtain further tumor reduction, the patient under-
went lateral segmentectomy of the liver (Figure 5a) and
microwave coagulation for multiple CCLM in the
remnant liver. At the second-look operation in this case,
obvious hepatotoxicities as such as steatohepatitis and
blue liver phenomenon were observed macroscopically.
Histology of the operative specimen showed a poorly dif-
ferentiated metastatic adenocarcinoma derived from
colon cancer (Figure 5b). As shown in Figure 6, post-
operative findings by abdominal enhanced CT displayed
no variable lesions in the remnant liver.
The patient obtained good quality of life (QOL) with
tumor dormancy by addition of the third line chemo-
therapy during the 6 months after the second operation.Figure 5 Surgical specimen and pathological findings of the second o
lateral segment of the liver. (b) Hemotoxylin and eosin staining (× 40) showHowever, his serum CEA level gradually re-increased
even though the third line chemotherapy with the com-
bination of cetuximab and irinotecan was performed
(Figure 2). Accordingly, a combination of FOLFOX6
with bevacizumab was chosen as the fourth line chemo-
therapy. His serum CEA level again decreased signifi-
cantly without any new lesions in the remnant liver. The
patient has kept a good QOL with tumor dormancy as
of 3 years after the first operation.
Discussion
Cetuximab, a new molecular drug with an extracellular
action site, is expected to remarkably suppress tumor
cell mitosis as an anti-EGFR monoclonal antibody [2].
Additionally, it is known that bevacizumab, a new
monoclonal antibody against VEGFR, also inhibits
tumor cell proliferation significantly by acting onperation. (a) The arrow indicated the cut face side of extirpated
ing a moderately differentiated adenocarcinoma.
Figure 6 Computed tomography showed multiple low-density
areas in the remnant liver following microwave coagulation.
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trial suggested that cetuximab with or without irinotecan
was effective in patients with irinotecan-refractory
CCLM [3]. Thereafter, cetuximab combined with che-
motherapies has led to a better prognosis, especially in
KRAS wild type patients with CCLM [4]. This was sup-
ported by the National Cancer Institute of Canada Clin-
ical Trials Group and Australasian Gastro-Intestinal
Trials Group CO.17 trial, which demonstrated that
cetuximab offers good QOL and survival benefits for
pretreated patients with advanced, wild-type KRAS colo-
rectal cancer [15]. A European Organisation for Re-
search and Treatment of Cancer trial demonstrated that
perioperative FOLFOX4 chemotherapy with surgery had
advantages over surgery alone [16]. Thus, to obtain pro-
longed survival of patients with CCLM, reduction sur-
gery may be effective. Adam et al. reported that
cetuximab rescued some patients with CCLM by in-
creasing the resectability of those tumors [5]. The
CELIM study by European groups suggested that neoad-
juvant chemotherapy with cetuximab yielded high re-
sponse rates and significantly increased resectability
when compared with historical controls [17]. A Euro-
pean Prospective Investigation into Cancer and Nutri-
tion study indicated that cetuximab with irinotecan
improved the QOL in patients with CCLM who failed to
exhibit a good response with fluoropyrimidine and oxali-
platin therapy [18]. Based on these previous studies, we
chose the combination therapy of cetuximab with irino-
tecan as the third line chemotherapy for our patient with
the wild type KRAS gene. Consequently, the patient
could undergo liver surgery and obtain a good QOL with
a significant reduction in his serum CEA level over the
next 6 months.
Some chemotherapeutic agents have been reported to
elicit hepatotoxicities, for example, irinotecan associated
with steatohepatitis [19]. Oxaliplatin has also inducedtoxic liver injury, which manifests as sinusoidal dilata-
tion or sinusoidal obstruction syndrome, namely blue
liver, and nodular regenerative hyperplasia [20]. However,
Pessaux et al. have suggested that popular chemotherapy
with cetuximab or bevacizumab is not associated with
definitive hepatotoxicities [21-23]. A recent study indi-
cated that bevacizumab suppresses oxaliplatin-induced
liver damage [24,25]. Although our patient’s liver demon-
strated an abnormal gross appearance, there was no
major impediment to performing the liver surgery safely.
Bevacizumab usually has been administrated with
FOLFIRI or FOLFOX as first line chemotherapy in
patients with CCLM and a poor prognosis, in the hope
of obtaining its additive effect [7-9]. However, some
reports have shown usefulness of bevacizumab-containing
therapy for advanced colorectal cancer patients after fail-
ure of irinotecan, oxaliplatin and cetuximab [10-13].
Results from these reports led us to choose a com-
bination of FOLFOX6 plus bevacizumab as the fourth
line chemotherapy.Conclusion
We here describe the successful management of a young
adult patient with CCLM with a liver surgery sand-
wiched between treatment with cetuximab and bevacizu-
mab, suggesting the possibility of bevacizumab
administration after cetuximab as a unique and effective
therapeutic modality.Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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